{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:06:47Z","timestamp":1790719607145,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":1857,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1017\/s1041610219000255","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T07:25:59Z","timestamp":1553153159000},"page":"1823-1829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prescribing trends and safety of clozapine in an older persons mental health population"],"prefix":"10.1016","volume":"31","author":[{"given":"Alice","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610219000255_bb0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1017\/S1041610219000255_bb0015","first-page":"CD006633","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","volume":"11","author":"Asenjo Lobos","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1017\/S1041610219000255_bb0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0010-440X(99)90134-7","article-title":"Clozapine in elderly psychiatric patients: Tolerability, safety and efficacy","volume":"40","author":"Barak","year":"1999","journal-title":"Comprehensive Psychiatry"},{"key":"10.1017\/S1041610219000255_bb0025","series-title":"Clopine tablets data sheet [online]","author":"Douglas Pharmaceuticals Ltd","year":"2010"},{"key":"10.1017\/S1041610219000255_bb0030","first-page":"CD000059","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","volume":"1","author":"Essali","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1017\/S1041610219000255_bb0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40263-017-0448-6","article-title":"Clozapine induced gastrointestinal hypo motility: A 22 year Bi-national pharmacovigilance study of serious or fatal \u2018slow gut\u2019 reactions and comparison with international drug safety advice","volume":"31","author":"Every-Palmer","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1017\/S1041610219000255_bb0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/089198879400700209","article-title":"Clozapine in the elderly","volume":"7","author":"Frankenburg","year":"1994","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1017\/S1041610219000255_bb0045","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1017\/S1041610219000255_bb0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14740338.7.5.525","article-title":"The safety of clozapine in the elderly","volume":"7","author":"Gareri","year":"2008","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1017\/S1041610219000255_bb0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1176\/appi.ps.002022012","article-title":"Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia","volume":"64","author":"G\u00f6ren","year":"2013","journal-title":"Psychiatric Services"},{"key":"10.1017\/S1041610219000255_bb0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.schres.2013.05.001","article-title":"Risk of neutropenia in a clozapine-treated elderly population","volume":"148","author":"Guenette","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1017\/S1041610219000255_bb0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.schres.2004.05.015","article-title":"Suicidal risk during treatment with clozapine: A meta-analysis","volume":"73","author":"Hennen","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1017\/S1041610219000255_bb0070","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00048679709073852","article-title":"Is clozapine safe in the elderly?","volume":"31","author":"Herst","year":"1997","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1017\/S1041610219000255_bb0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1471-2458-7-220","article-title":"Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: The Norwegian HUNT 2 study","volume":"7","author":"Hildrum","year":"2007","journal-title":"BMC Public Health"},{"key":"10.1017\/S1041610219000255_bb0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.schres.2013.07.043","article-title":"Antipsychotics and mortality in first-onset schizophrenia: Prospective Finnish register study with 5-year follow-up","volume":"150","author":"Kiviniemi","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1017\/S1041610219000255_bb0085","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1176\/ajp.2006.163.7.1273","article-title":"Prevalence of the metabolic syndrome among patients receiving clozapine","volume":"163","author":"Lamberti","year":"2006","journal-title":"The American Journal of Psychiatry"},{"key":"10.1017\/S1041610219000255_bb0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1017\/S1041610219000255_bb0095","first-page":"CD005580","article-title":"Antipsychotic medication for elderly people with schizophrenia","volume":"1","author":"Marriott","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1017\/S1041610219000255_bb0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610219000255_bb0105","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","article-title":"Life-threatening clozapine-induced gastrointestinal hypo motility: An analysis of 102 cases","volume":"69","author":"Palmer","year":"2008","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610219000255_bb0110","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1192\/pb.30.11.410","article-title":"Survey of clozapine use by consultant old age psychiatrists","volume":"30","author":"Paranthaman","year":"2006","journal-title":"Psychiatric Bulletin"},{"key":"10.1017\/S1041610219000255_bb0115","first-page":"180","article-title":"Efficacy and adverse effects of clozapine in four elderly psychotic patients","volume":"56","author":"Pitner","year":"1995","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610219000255_bb0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S1041610214001756","article-title":"Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia","volume":"27","author":"Pridan","year":"2015","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610219000255_bb0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1017\/S1041610219000255_bb0130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1099-1166(199705)12:5<553::AID-GPS547>3.0.CO;2-U","article-title":"Outcome of clozapine therapy for elderly patients with refractory primary psychosis","volume":"12","author":"Sajatovic","year":"1996","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610219000255_bb0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00019442-199524310-00004","article-title":"Clozapine in older patients with psychosis and behavioural disruption","volume":"3","author":"Salzman","year":"1995","journal-title":"The American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610219000255_bb0140","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1503\/cmaj.061250","article-title":"Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients","volume":"176","author":"Schneeweiss","year":"2007","journal-title":"Canadian Medical Association Journal"},{"key":"10.1017\/S1041610219000255_bb0145","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0269881113482530","article-title":"Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: A population-based, case-crossover study","volume":"27","author":"Shin","year":"2013","journal-title":"Journal of Psychopharmacology"},{"key":"10.1017\/S1041610219000255_bb0150","first-page":"113","article-title":"Treatment of elderly institutionalised patients with clozapine","volume":"33","author":"Shulman","year":"1997","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1017\/S1041610219000255_bb0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/YIC.0b013e32834405fc","article-title":"A study of the use of clozapine in old age psychiatry","volume":"26","author":"Snowdon","year":"2011","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1017\/S1041610219000255_bb0160","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.chest.2016.06.004","article-title":"Antipsychotic use and risk of hospitalisation or death due to pneumonia in persons with and without Alzheimer\u2019s disease","volume":"150","author":"Tolppanen","year":"2016","journal-title":"Chest"},{"key":"10.1017\/S1041610219000255_bb0165","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00001648-199710000-00010","article-title":"Mortality in current and former users of clozapine","volume":"8","author":"Walker","year":"1997","journal-title":"Epidemiology"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224024207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224024207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610219000255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T22:09:18Z","timestamp":1736460558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224024207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1041610224024207"],"URL":"https:\/\/doi.org\/10.1017\/s1041610219000255","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing trends and safety of clozapine in an older persons mental health population","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610219000255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 International Psychogeriatric Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}